Reported Earnings • Aug 04
Second quarter 2026 earnings released: EPS: €0.21 (vs €0.21 in 2Q 2025) Second quarter 2026 results: EPS: €0.21 (in line with 2Q 2025). Revenue: €209.3m (up 4.7% from 2Q 2025). Net income: €9.81m (flat on 2Q 2025). Profit margin: 4.7% (down from 4.9% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 22
Upcoming dividend of €0.04 per share Eligible shareholders must have bought the stock before 29 May 2026. Payment date: 02 June 2026. Payout ratio is a comfortable 6.5% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (3.0%). Declared Dividend • Apr 16
Dividend of €0.04 announced Dividend of €0.04 is the same as last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 1.2%, which is lower than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (4% cash payout ratio). The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 42% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Apr 16
MEDICLIN Aktiengesellschaft announces Annual dividend, payable on June 02, 2026 MEDICLIN Aktiengesellschaft announced Annual dividend of EUR 0.0400 per share payable on June 02, 2026, ex-date on May 29, 2026 and record date on June 01, 2026. Reported Earnings • Mar 30
Full year 2025 earnings released: EPS: €0.54 (vs €0.52 in FY 2024) Full year 2025 results: EPS: €0.54 (up from €0.52 in FY 2024). Revenue: €804.3m (up 5.6% from FY 2024). Net income: €25.5m (up 2.6% from FY 2024). Profit margin: 3.2% (down from 3.3% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 2 years compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Price Target Changed • Jan 12
Price target increased by 35% to €7.00 Up from €5.20, the current price target is provided by 1 analyst. New target price is 87% above last closing price of €3.74. Stock is up 56% over the past year. The company posted earnings per share of €0.52 last year. Reported Earnings • Nov 09
Third quarter 2025 earnings released: EPS: €0.33 (vs €0.30 in 3Q 2024) Third quarter 2025 results: EPS: €0.33 (up from €0.30 in 3Q 2024). Revenue: €210.1m (up 8.0% from 3Q 2024). Net income: €15.4m (up 7.7% from 3Q 2024). Profit margin: 7.3% (in line with 3Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 4.4% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 03
Second quarter 2025 earnings released: EPS: €0.20 (vs €0.04 in 2Q 2024) Second quarter 2025 results: EPS: €0.20 (up from €0.04 in 2Q 2024). Revenue: €203.4m (up 8.6% from 2Q 2024). Net income: €9.88m (up 395% from 2Q 2024). Profit margin: 4.9% (up from 1.1% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 29
Upcoming dividend of €0.04 per share Eligible shareholders must have bought the stock before 05 June 2025. Payment date: 10 June 2025. The company last paid an ordinary dividend in March 2018. The average dividend yield among industry peers is 2.5%. Reported Earnings • May 05
First quarter 2025 earnings released First quarter 2025 results: Revenue: €192.4m (flat on 1Q 2024). Net loss: €162.8k (loss narrowed 88% from 1Q 2024). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. New Risk • Apr 25
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 28
Full year 2024 earnings released: EPS: €0.52 (vs €0.23 loss in FY 2023) Full year 2024 results: EPS: €0.52 (up from €0.23 loss in FY 2023). Revenue: €765.1m (flat on FY 2023). Net income: €24.8m (up €35.6m from FY 2023). Profit margin: 3.2% (up from net loss in FY 2023). Revenue is forecast to grow 1.9% p.a. on average during the next 2 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Price Target Changed • Mar 16
Price target increased by 9.5% to €5.20 Up from €4.75, the current price target is provided by 1 analyst. New target price is 79% above last closing price of €2.90. Stock is up 26% over the past year. The company posted a net loss per share of €0.23 last year. Announcement • Jan 23
MEDICLIN Aktiengesellschaft Raises Earnings Guidance for the Year 2024 MEDICLIN Aktiengesellschaft raised earnings guidance for the year 2024. Instead of a Group EBIT between EUR 33.0 million and 39.0 million, the company now expects a Group EBIT between EUR 48.0 million and 54.0 million. The sales forecast for the Group was raised from -2.0% to 0.0% to now 1.0% to 3.0%. New Risk • Jan 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 05
Third quarter 2024 earnings released: EPS: €0.29 (vs €0.22 in 3Q 2023) Third quarter 2024 results: EPS: €0.29 (up from €0.22 in 3Q 2023). Revenue: €194.7m (up 1.0% from 3Q 2023). Net income: €14.3m (up 36% from 3Q 2023). Profit margin: 7.3% (up from 5.4% in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Aug 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to €2.50. The fair value is estimated to be €3.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Aug 09
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to €2.58. The fair value is estimated to be €3.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: €0.01 (vs €0.23 in 2Q 2023) Second quarter 2024 results: EPS: €0.01 (down from €0.23 in 2Q 2023). Revenue: €187.2m (down 4.0% from 2Q 2023). Net income: €2.00m (down 82% from 2Q 2023). Profit margin: 1.1% (down from 5.7% in 2Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 04
First quarter 2024 earnings released: €0.03 loss per share (vs €0.13 loss in 1Q 2023) First quarter 2024 results: €0.03 loss per share (improved from €0.13 loss in 1Q 2023). Revenue: €191.8m (up 5.7% from 1Q 2023). Net loss: €1.40m (loss narrowed 78% from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Mar 28
MEDICLIN Aktiengesellschaft, Annual General Meeting, Jun 06, 2024 MEDICLIN Aktiengesellschaft, Annual General Meeting, Jun 06, 2024. Reported Earnings • Mar 28
Full year 2023 earnings released: €0.23 loss per share (vs €0.20 profit in FY 2022) Full year 2023 results: €0.23 loss per share (down from €0.20 profit in FY 2022). Revenue: €766.7m (up 6.7% from FY 2022). Net loss: €10.8m (down 214% from profit in FY 2022). Revenue is expected to decline by 2.3% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.4%. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Mar 01
MEDICLIN Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Mar 26, 2024 MEDICLIN Aktiengesellschaft announced that they will report fiscal year 2023 final results on Mar 26, 2024 Buying Opportunity • Jan 17
Now 22% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be €3.42, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 2.2% in 2 years. Earnings is forecast to grow by 2.9% in the next 2 years. Reported Earnings • Nov 06
Third quarter 2023 earnings released: EPS: €0.22 (vs €0.043 in 3Q 2022) Third quarter 2023 results: EPS: €0.22 (up from €0.043 in 3Q 2022). Revenue: €192.8m (up 10% from 3Q 2022). Net income: €10.5m (up 413% from 3Q 2022). Profit margin: 5.4% (up from 1.2% in 3Q 2022). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 1.2% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Sep 22
MEDICLIN Aktiengesellschaft Appoints Thomas Piefke as A Member of Management Board. Effective October 1, 2023 MEDICLIN Aktiengesellschaft appointed Thomas Piefke as a member of MEDICLIN’s Management Board. Effective October 1, 2023, Thomas Piefke will succeed Dr. York Dhein, who will resign from his position as a member of the company’s Management Board by mutual agreement with the Supervisory Board on September 30, 2023, to pursue new professional challenges. Thomas Piefke has been active in leading positions in the healthcare sector for about 27 years. A graduate in health economics, he worked for many years as a regional manager for rehabilitation and managing director of a major German clinic providers across Germany before joining the Asklepios Group as managing director in 2017. He currently heads the Asklepios Nordseeklinik Westerland/Sylt, a large rehabilitation clinic and an acute clinic work closely together under one roof. New Risk • Aug 02
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.6% Last year net profit margin: 2.7% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.6% net profit margin). Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: €0.23 (vs €0.13 in 2Q 2022) Second quarter 2023 results: EPS: €0.23 (up from €0.13 in 2Q 2022). Revenue: €195.1m (up 5.8% from 2Q 2022). Net income: €11.0m (up 79% from 2Q 2022). Profit margin: 5.7% (up from 3.3% in 2Q 2022). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • May 07
First quarter 2023 earnings released: €0.13 loss per share (vs €0.081 loss in 1Q 2022) First quarter 2023 results: €0.13 loss per share (further deteriorated from €0.081 loss in 1Q 2022). Revenue: €181.4m (up 2.6% from 1Q 2022). Net loss: €6.27m (loss widened 63% from 1Q 2022). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • May 05
Mercurius Health, S.A. completed the acquisition of MEDICLIN Robert Janker Klinik from MEDICLIN Aktiengesellschaft. Mercurius Health, S.A. agreed to acquire MEDICLIN Robert Janker Klinik from MEDICLIN Aktiengesellschaft on January 11, 2023. The deal is subject to regulatory approval.Mercurius Health, S.A. completed the acquisition of MEDICLIN Robert Janker Klinik from MEDICLIN Aktiengesellschaft on May 4, 2023. Buying Opportunity • Nov 18
Now 20% undervalued Over the last 90 days, the stock is up 9.4%. The fair value is estimated to be €4.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 4.3% in 2 years. Earnings is forecast to grow by 4.5% in the next 2 years. Price Target Changed • Nov 16
Price target increased to €6.10 Up from €5.40, the current price target is provided by 1 analyst. New target price is 75% above last closing price of €3.48. Stock is down 13% over the past year. The company posted earnings per share of €0.031 last year. Buying Opportunity • Nov 03
Now 20% undervalued Over the last 90 days, the stock is up 7.4%. The fair value is estimated to be €4.38, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 4.3% in 2 years. Earnings is forecast to decline by 8.4% in the next 2 years. Valuation Update With 7 Day Price Move • Oct 27
Investor sentiment improved over the past week After last week's 17% share price gain to €3.66, the stock trades at a trailing P/E ratio of 9x. Average forward P/E is 12x in the Healthcare industry in Germany. Total loss to shareholders of 34% over the past three years. Reported Earnings • Jul 30
Second quarter 2022 earnings released: €0.13 loss per share (vs €0.08 loss in 2Q 2021) Second quarter 2022 results: €0.13 loss per share. Revenue: €184.4m (up 11% from 2Q 2021). Net income: €6.16m (up €10.1m from 2Q 2021). Profit margin: 3.3% (up from net loss in 2Q 2021). Over the next year, revenue is forecast to stay flat compared to a 3.8% growth forecast for the industry in Germany. Announcement • Jul 30
MEDICLIN Aktiengesellschaft Provides Earnings Guidance for the Year 2022 MEDICLIN Aktiengesellschaft provided earnings guidance for the year 2022. For the 2022 financial year, the Management Board continues to expect Group sales and Group operating result to be higher than in the previous year. Reported Earnings • May 03
First quarter 2022 earnings released: €0.08 loss per share (vs €0.24 loss in 1Q 2021) First quarter 2022 results: €0.08 loss per share (up from €0.24 loss in 1Q 2021). Revenue: €176.7m (up 13% from 1Q 2021). Net loss: €3.85m (loss narrowed 67% from 1Q 2021). Over the next year, revenue is forecast to grow 2.0%, compared to a 5.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: €0.03 (vs €0.19 loss in FY 2020) Full year 2021 results: EPS: €0.03 (up from €0.19 loss in FY 2020). Revenue: €687.1m (up 3.8% from FY 2020). Net income: €1.46m (up €10.5m from FY 2020). Profit margin: 0.2% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 2.9%, compared to a 4.4% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Announcement • Mar 01
MEDICLIN Aktiengesellschaft to Report Fiscal Year 2021 Results on Mar 30, 2022 MEDICLIN Aktiengesellschaft announced that they will report fiscal year 2021 results on Mar 30, 2022 Reported Earnings • Nov 03
Third quarter 2021 earnings released: EPS €0.22 (vs €0.14 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €183.9m (up 3.5% from 3Q 2020). Net income: €10.8m (up 64% from 3Q 2020). Profit margin: 5.9% (up from 3.7% in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Executive Departure • Aug 04
Chairman of Management Board & CEO Volker Hippler has left the company On the 1st of August, Volker Hippler was replaced as CEO by Joachim Ramming after 5.3 years in the role. We don't have any record of a personal shareholding under Volker's name. Volker is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.58 years, which is considered inexperienced in the Simply Wall St Risk Model. Under Volker's leadership, the company delivered a total shareholder return of -19%. Reported Earnings • Aug 03
Second quarter 2021 earnings released: €0.08 loss per share (vs €0.12 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: €166.8m (up 6.8% from 2Q 2020). Net loss: €3.97m (loss narrowed 33% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Announcement • Mar 28
MEDICLIN AG Provides Earnings Guidance for the Year 2021 MEDICLIN AG provided earnings guidance for the year 2021. As far as the forecast for 2021 is concerned, this is based on the findings of the previous year in terms of sales and earnings development. MEDICLIN expects the full year 2021 to be similar to that of 2020, but this depends on the pandemic, in particular its duration compared to the 2020 financial year, and the state protective shield benefits in 2021. Is New 90 Day High Low • Feb 15
New 90-day high: €4.42 The company is up 18% from its price of €3.74 on 17 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. Announcement • Jan 13
Mediclin AG Appoints York Dhein as Additional Member to the Management Board, Effective April 1, 2021 The Supervisory Board of MEDICLIN Aktiengesellschaft appointed Dr. med. York Dhein as additional member to the Management Board of MEDICLIN AG. The 54-year-old is a specialist in internal medicine and, after working in a clinic, worked for a large company health insurance fund for several years, last as head of care and contract management. York Dhein stands up for a stronger position of rehabilitation in the health sector for years. Dr. York Dhein will join on April 1, 2021. Is New 90 Day High Low • Jan 04
New 90-day high: €4.00 The company is up 5.0% from its price of €3.80 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 3.0% over the same period. Announcement • Nov 20
MEDICLIN Aktiengesellschaft, Annual General Meeting, May 27, 2021 MEDICLIN Aktiengesellschaft, Annual General Meeting, May 27, 2021. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS €0.12 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €177.7m (up 3.6% from 3Q 2019). Net income: €6.56m (up 31% from 3Q 2019). Profit margin: 3.7% (up from 2.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Nov 05
New 90-day low: €3.70 The company is down 6.0% from its price of €3.92 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 8.0% over the same period. Announcement • Aug 24
MediClin AG Announces Reliable Forecast for the 2020 Financial Year Is Not Yet Possible MediClin AG announced that corona-related precautious free capacities reserved as a precaution in the second quarter of 2020 led to a decline in sales and earnings in the Group - a reliable forecast for the 2020 financial year is not yet possible. Announcement • Aug 01
District of Ludwigslust-Parchim signed a letter of intent to acquire an unknown stake in MediClin Krankenhaus am Crivitzer See GmbH from MEDICLIN Aktiengesellschaft (XTRA:MED). District of Ludwigslust-Parchim signed a letter of intent to acquire an unknown stake in MediClin Krankenhaus am Crivitzer See GmbH from MEDICLIN Aktiengesellschaft (XTRA:MED) in June 2020. 
